Achieve Life Sciences, Inc. (ACHV) is a publicly traded Healthcare sector company. As of July 28, 2026, ACHV trades at $6.18 with a market cap of $634.43M and a P/E ratio of -4.90. ACHV moved -0.32% today. Year to date, ACHV is +24.35%; over the trailing twelve months it is +129.74%. Its 52-week range spans $1.84 to $7.11. Analyst consensus is strong buy with an average price target of $14.33. Rallies surfaces ACHV's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Achieve Life Sciences Added to Russell 2000 Index, Gaining Exposure to $12.2T Benchmarks: Achieve Life Sciences was added to the Russell 2000 Index effective June 26, 2026 as part of the Russell U.S. Indexes reconstitution. The inclusion increases exposure to institutional investors tracking approximately $12.2 trillion in Russell benchmarks and could enhance demand for its late-stage cytisinicline nicotine-dependence therapy.
| Metric | Value |
|---|---|
| Price | $6.18 |
| Market Cap | $634.43M |
| P/E Ratio | -4.90 |
| EPS | $-1.25 |
| Dividend Yield | 0.00% |
| 52-Week High | $7.11 |
| 52-Week Low | $1.84 |
| Volume | 1.07M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-54.65M |
| Gross Margin | 0.00% |
6 analysts cover ACHV: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $14.33.